以原发性纤溶亢进为首发表现的转移性前列腺癌1例报告并文献复习  

A case report and literature review of metastatic prostate cancer with primary hyperfibrinolysis as the first presentation

作　　者：宋玉华 彭鹏 陆化[3] 龙启强 Song Yuhua;Peng Peng;Lu Hua;Long Qiqiang(Department of Haematology,The Second Hospital of Nanjing,Nanjing University of Chinese Medicine Nanjing,Jiangsu Province,210003,China;Department of Oncology,The Second Hospital of Nanjing,Nanjing University of Chinese Medicine Nanjing,Jiangsu Province,210003,China;Department of Haematology,First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing,Jiangsu Province,210003,China)

机构地区：[1]南京中医药大学附属南京医院、南京市第二医院血液科,南京210003 [2]南京中医药大学附属南京医院、南京市第二医院肿瘤科,南京210003 [3]南京医科大学附属第一医院、江苏省人民医院血液科,南京210029

出　　处：《中国综合临床》2023年第6期471-474,共4页Clinical Medicine of China

摘　　要：转移性前列腺癌并发原发性纤溶亢进继发出血综合征临床罕见。出血性疾病的正确诊断是选择正确治疗的前提。氨甲环酸可作为原发性纤溶亢进引发出血患者的首选治疗。抗纤溶药和抗雄激素治疗的结合可有效控制转移性前列腺癌中原发性纤溶亢进引起的严重出血症状。原发性纤溶亢进的早诊断、早治疗对于控制出血和改善预后至关重要。We reported a rare case with metastatic prostate cancer complicated with hemorrhagic syndrome caused byprimary hyperfibrinolysis.The correct diagnosis of bleeding disorders is a prerequisite for choosing the correct treatment.Tranexamic acid can be used as the preferred treatment for patients with bleeding caused by primary hyperfibrinolysis.In this case,the combination of antifibrinolytics and antiandrogen therapy effectively controlled the severe bleeding symptoms caused by primary hyperfibrinolysis in metastatic prostate cancer.Appropriate treatment after early diagnosis is essential to prevent bleeding and improve prognosis.

关 键 词：转移性前列腺癌 出血综合征 原发性纤溶亢进 抗纤溶药 抗雄激素治疗 

分 类 号：R737.25[医药卫生—肿瘤]